PanGIA Biotech Expands Leadership Team, Appoints Curtiss McNair as Vice President of Operations

DELRAY BEACH, Fla.--(BUSINESS WIRE)--PanGIA Biotech, a leader in true liquid biopsy technology, is pleased to announce the appointment of Curtiss McNair as Vice President of Operations. With over 20 years of experience in laboratory management, clinical trials, and operational strategy, McNair’s transformative leadership will help PanGIA Biotech fulfill its mission to transform disease detection and improve healthcare outcomes globally.

Known for adapting and thriving in demanding environments, McNair will oversee manufacturing, clinical laboratory operations, and IT services while driving scalable processes and aligning resources to support PanGIA Biotech’s mission.

“Curtiss brings the operational expertise and strategic vision we need to scale our innovations and deliver meaningful results,” said Holly Magliochetti, CEO & Co-Founder of PanGIA Biotech. “His ability to optimize processes and foster collaboration will empower clinicians, improve patient outcomes, and strengthen our fight against cancer with cutting-edge diagnostics.”

With a reputation for building high-performing teams and executing strategic initiatives that drive efficiency that aligns with organizational goals, this Rochester, NY-native holds an MBA from Ashford University, and a Bachelor of Science in Chemistry from Victory University. Currently defending his Ph.D. dissertation on Organizational Leadership at Carolina University, McNair’s innovative thinking supports PanGIA Biotech’s mission to create transformative healthcare changes.

“I’m honored to join PanGIA Biotech and contribute to groundbreaking advancements in diagnostic technology,” said McNair. “This role provides unique opportunities to combine my expertise with PanGIA Biotech’s innovative approach to healthcare, ensuring the company delivers value to its stakeholders while transforming patient outcomes worldwide.”

McNair’s appointment underscores PanGIA Biotech’s commitment to operational excellence, building stakeholder confidence, and positioning the company for continued growth and innovation.

About PanGIA Biotech

PanGIA Biotech develops AI-integrated liquid biopsy technology designed for global scalability. The PanGIA® platform is a transformative solution for detecting, monitoring, and managing diseases, including cancers as early as Stage 1. Powered by machine learning, this urine-based platform profiles biomolecular patterns to deliver accurate diagnostic insights. PanGIA Biotech’s technology is grounded in peer-reviewed research and R&D success, supported by patents to the company for global diagnostic development. With steadfast commitment to research and innovation, PanGIA Biotech’s vision is to revolutionize disease detection and improve healthcare worldwide. For more information, visit www.PanGIABiotech.com.